As the financial landscape increasingly intertwines with digital assets, companies are exploring innovative ways to integrate cryptocurrency into their business strategies. This shift reflects a broader trend of traditional firms seeking to enhance their financial reserves and capitalize on the burgeoning decentralized finance ecosystem.

Helius Medical Technologies, Inc. ( HSDT ) stock is skyrocketing on Monday, with a session volume of 17.89 million compared to the average volume of 351.807 thousand after the company priced an oversubscribed private investment in public equity offering shares and pre-funded warrants at a purchase price of $6.881 and stapled warrants.

HSDT is surging to new heights today. Follow the breaking news here.

The offering consists of over $500 million in proceeds and over an additional $750 million in stapled warrants to purchase shares. The stapled warrants will be exercisable for a period of three years from the date of issuance and have an exercise price equal to $10.134 per stapled warrant.

The company plans to use the net proceeds to implement a digital asset treasury strategy and acquire Solana tokens (CRYPTO: SOL), the native cryptocurrency of the Solana blockchain.

SOL will serve as the company’s primary treasury reserve asset.

The company intends to leverage the native yield-generating properties of Solana’s architecture – and capture opportunities in DeFi and broader on-chain activity.

SOL Treasury Strategy and Institutional Roadmap

After the deal closes, the Company plans to:

Establish an initial position in SOL and gradually expand its holdings over the next 12–24 months through a structured capital markets program that may include at-the-market offerings and other established financing methods.

Explore staking, lending, and additional opportunities within the Solana ecosystem to generate income from its SOL treasury, while prioritizing a cautious and risk-aware approach.

In July, Helius Medical ( HSDT ) announced a positive outcome from the Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program.

Helius Medical ( HSDT ) said key primary outcomes indicate its randomized clinical trial of active PoNS therapy met its primary endpoint, demonstrating statistically significant improvements in gait and/or balance deficit due to stroke.

The company noted the study showed good tolerability and minimal adverse event incidents.

HSDT Price Action: Helius Medical Tech ( HSDT ) shares were up 154.10% at $19.21 at the time of publication on Monday. The stock is trading near its 52-week low of $5.37, according to Benzinga Pro data.

Read Next:

Hain Celestial Faces Steeper Losses As Impairment Charges Hit Weak Sales